$8.44
0.96% yesterday
Nasdaq, Nov 07, 10:00 pm CET
ISIN
US3984384087
Symbol
GRFS

Grifols, S.A. Sponsored ADR Class B Stock price

$8.44
-1.15 11.99% 1M
+1.12 15.30% 6M
+1.00 13.44% YTD
-1.06 11.16% 1Y
+1.45 20.74% 3Y
-11.16 56.94% 5Y
-9.02 51.67% 10Y
+1.83 27.66% 20Y
Nasdaq, Closing price Fri, Nov 07 2025
+0.08 0.96%
ISIN
US3984384087
Symbol
GRFS
Industry

Key metrics

Basic
Market capitalization
$7.2b
Enterprise Value
$16.7b
Net debt
$9.4b
Cash
$951.1m
Shares outstanding
679.7m
Valuation (TTM | estimate)
P/E
16.5 | 9.2
P/S
0.8 | 0.8
EV/Sales
1.9 | 1.9
EV/FCF
18.0
P/B
1.2
Dividends
DPS
$0.00
Yield 1Y | 5Y
0.0% | 1.1%
Growth 1Y | 5Y
- | -100.0%
Payout 1Y | 3Y
0.0% | 0.0%
Increased
0 Years
Financials (TTM | estimate)
Revenue
$8.6b | $8.8b
EBITDA
$1.6b | $2.2b
EBIT
$1.5b | $1.6b
Net Income
$344.1m | $624.3m
Free Cash Flow
$923.5m
Growth (TTM | estimate)
Revenue
9.3% | 5.3%
EBITDA
38.5% | 41.5%
EBIT
44.1% | 20.1%
Net Income
100.8% | 243.9%
Free Cash Flow
257.8%
Margin (TTM | estimate)
Gross
39.4%
EBITDA
18.9% | 24.6%
EBIT
17.8%
Net
4.0% | 7.1%
Free Cash Flow
10.7%
Financial Health
Equity Ratio
27.5%
Return on Equity
2.7%
ROCE
7.5%
ROIC
4.8%
Debt/Equity
1.7
More
EPS
$0.5
FCF per Share
$1.4
Short interest
0.4%
Employees
24k
Rev per Employee
$350.0k
Show more

Is Grifols, S.A. Sponsored ADR Class B a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.

Grifols, S.A. Sponsored ADR Class B Stock Analysis

Unlock Scores for Free

Analyst Opinions

20 Analysts have issued a Grifols, S.A. Sponsored ADR Class B forecast:

14x Buy
70%
4x Hold
20%
2x Sell
10%

Analyst Opinions

20 Analysts have issued a Grifols, S.A. Sponsored ADR Class B forecast:

Buy
70%
Hold
20%
Sell
10%

Financial data from Grifols, S.A. Sponsored ADR Class B

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
8,614 8,614
9% 9%
100%
- Direct Costs 5,222 5,222
8% 8%
61%
3,392 3,392
12% 12%
39%
- Selling and Administrative Expenses 1,341 1,341
8% 8%
16%
- Research and Development Expense 425 425
7% 7%
5%
1,625 1,625
38% 38%
19%
- Depreciation and Amortization 93 93
16% 16%
1%
EBIT (Operating Income) EBIT 1,533 1,533
44% 44%
18%
Net Profit 344 344
101% 101%
4%

In millions USD.

Don't miss a Thing! We will send you all news about Grifols, S.A. Sponsored ADR Class B directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Grifols, S.A. Sponsored ADR Class B Stock News

Neutral
Seeking Alpha
3 days ago
Grifols, S.A. (OTCPK:GIKLY) Q3 2025 Earnings Call November 4, 2025 12:30 PM EST Company Participants Daniel Segarra - Head of Investor Relations & Sustainability and Vice President Jose Ignacio Abia Buenache - CEO & Director Roland Wandeler - President of Biopharma Business Unit Rahul Srinivasan - Chief Financial Officer Conference Call Participants Charles Pitman - Barclays Bank PLC, Research ...
Positive
Seeking Alpha
4 days ago
Biotech stocks have rebounded after years of underperformance but remain well below their 2021 highs. Successful drug launches, strong trial results, and falling interest rates have boosted stock prices, while M&A activity pushes valuations higher. The biotech rally could be sustainable, analysts say, with biotech firms more disciplined and increasingly profitable, while startups avoid launchin...
Positive
Seeking Alpha
9 days ago
The current market is all about momentum, but investors don't need to buy overpriced high-growth stocks to participate in gains. If you dig deep enough, you can find undervalued stocks with growth potential in both the short term and the long run. Across varied sectors like healthcare, technology, and finance, as well as non-U.S. countries with growth potential, a select group of stocks can com...
More Grifols, S.A. Sponsored ADR Class B News

Company Profile

Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.

Head office Spain
CEO Nacho Abia
Employees 23,833
Founded 1940
Website www.grifols.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today